| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2004PNAS..101.4649M |
| P356 | DOI | 10.1073/PNAS.0400590101 |
| P932 | PMC publication ID | 384801 |
| P698 | PubMed publication ID | 15070772 |
| P5875 | ResearchGate publication ID | 8630544 |
| P2093 | author name string | Masashi Yanagisawa | |
| Takeshi Sakurai | |||
| Christopher M Sinton | |||
| Jon T Willie | |||
| Junko Hara | |||
| Michihiro Mieda | |||
| P2860 | cites work | Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior | Q24315738 |
| Efficient selection for high-expression transfectants with a novel eukaryotic vector | Q27860810 | ||
| The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene | Q28142783 | ||
| A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains | Q28145391 | ||
| To eat or to sleep? Orexin in the regulation of feeding and wakefulness | Q28209925 | ||
| Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation | Q29615680 | ||
| Neurons containing hypocretin (orexin) project to multiple neuronal systems | Q29619641 | ||
| Orexin A activates locus coeruleus cell firing and increases arousal in the rat. | Q30504135 | ||
| Orexins/hypocretins in the ob/ob mouse: hypothalamic gene expression, peptide content and metabolic effects | Q30671606 | ||
| The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats | Q33892990 | ||
| Reduced number of hypocretin neurons in human narcolepsy | Q33923479 | ||
| Arousal effect of orexin A depends on activation of the histaminergic system | Q33934848 | ||
| Narcolepsy: a neurodegenerative disease of the hypocretin system? | Q34072315 | ||
| The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias | Q34153927 | ||
| Pharmacological aspects of human and canine narcolepsy | Q34740875 | ||
| Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders | Q34982306 | ||
| The neurobiology, diagnosis, and treatment of narcolepsy | Q35056487 | ||
| Strain differences in amphetamine sensitivity in mice. II. Overcompensation of paradoxical sleep after deprivation in two C57 strains | Q40287373 | ||
| Distribution of orexin neurons in the adult rat brain | Q42471901 | ||
| Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs | Q43780972 | ||
| Neuroendocrine and electroencephalographic sleep changes due to acute amphetamine ingestion in human beings | Q43897126 | ||
| Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: implications for arousal via a mechanism of hippocampal disinhibition. | Q44115086 | ||
| Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes | Q44472346 | ||
| Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs | Q46143346 | ||
| Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. | Q46241302 | ||
| Effects of orexin-A on memory processing | Q48491130 | ||
| Circadian-dependent and circadian-independent behavioral actions of hypocretin/orexin | Q48558685 | ||
| Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity | Q48691942 | ||
| Hypocretin (orexin) deficiency in human narcolepsy. | Q55033530 | ||
| Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat | Q73025103 | ||
| Independent feeding and metabolic actions of orexins in mice | Q77760660 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | narcolepsy | Q189561 |
| cataplexy | Q944473 | ||
| P304 | page(s) | 4649-4654 | |
| P577 | publication date | 2004-03-16 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice | |
| P478 | volume | 101 |
| Q88307742 | A comparison of the orexin receptor distribution in the brain between diurnal Nile grass rats (Arvicanthis niloticus) and nocturnal mice (Mus musculus) |
| Q24623713 | A practical guide to the therapy of narcolepsy and hypersomnia syndromes |
| Q37080576 | Addiction and arousal: the hypocretin connection. |
| Q36608029 | Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy |
| Q36764549 | Animal models of narcolepsy |
| Q92878428 | Arousal and sleep circuits |
| Q37364821 | Attenuated cold defense responses in orexin neuron-ablated rats |
| Q36297727 | Brain orexin promotes obesity resistance. |
| Q38684472 | Challenges in the development of therapeutics for narcolepsy |
| Q36047054 | Chemistry and biology of orexin signaling |
| Q35630404 | Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women |
| Q64904970 | Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. |
| Q48459026 | Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice |
| Q24634619 | Control of sleep and wakefulness |
| Q36079899 | Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice |
| Q38152336 | Current and emerging options for the drug treatment of narcolepsy |
| Q47647264 | Dietary therapy restores glutamatergic input to orexin/hypocretin neurons after traumatic brain injury in mice |
| Q41818726 | Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep |
| Q35084855 | Discovery Of An Orexin Receptor Positive Potentiator |
| Q83232822 | Dissociating orexin-dependent and -independent functions of orexin neurons using novel Orexin-Flp knock-in mice |
| Q47657713 | Dual-transmitter systems regulating arousal, attention, learning and memory. |
| Q48344885 | Ectopic overexpression of orexin alters sleep/wakefulness states and muscle tone regulation during REM sleep in mice |
| Q35149403 | Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats |
| Q35222160 | Effects of orexin 2 receptor activation on apnea in the C57BL/6J mouse |
| Q36473239 | Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice |
| Q37694570 | Emerging treatments for narcolepsy and its related disorders |
| Q26830022 | Energy expenditure: role of orexin |
| Q37071459 | Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity |
| Q30431076 | Forebrain networks and the control of feeding by environmental learned cues |
| Q53417068 | Functional Changes Induced by Orexin A and Adiponectin on the Sympathetic/Parasympathetic Balance. |
| Q39140728 | GABA Cells in the Central Nucleus of the Amygdala Promote Cataplexy. |
| Q42067265 | GABA Receptors on Orexin and Melanin-Concentrating Hormone Neurons Are Differentially Homeostatically Regulated Following Sleep Deprivation. |
| Q48223052 | Genetic ablation of hypocretin neurons alters behavioral state transitions in zebrafish. |
| Q47118659 | Global analysis of gene expression mediated by OX1 orexin receptor signaling in a hypothalamic cell line. |
| Q48485373 | High cortisol response to adrenocorticotrophic hormone identifies ewes with reduced melanocortin signalling and increased propensity to obesity. |
| Q35591448 | Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level |
| Q34155661 | Hypocretin and its emerging role as a target for treatment of sleep disorders |
| Q37738130 | Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights |
| Q36891142 | Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy |
| Q33814590 | Hypocretin/orexin and narcolepsy: new basic and clinical insights |
| Q34593415 | Hypocretin/orexin overexpression induces an insomnia-like phenotype in zebrafish. |
| Q35948120 | Hypocretin/orexin prevents recovery from sickness |
| Q48449697 | Hypocretin/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress |
| Q36260008 | Hypocretins (orexins) and sleep-wake disorders |
| Q90668231 | Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex |
| Q38284819 | Interactions of the orexin/hypocretin neurones and the histaminergic system |
| Q38654594 | Investigational therapies for the treatment of narcolepsy. |
| Q38678290 | Is Sleep Disruption a Risk Factor for Alzheimer's Disease? |
| Q38836508 | Japanese sake yeast supplementation improves the quality of sleep: a double-blind randomised controlled clinical trial |
| Q37700398 | Lack of hypocretin attenuates behavioral changes produced by glutamatergic activation of the perifornical-lateral hypothalamic area |
| Q36245127 | Learning and the motivation to eat: forebrain circuitry |
| Q38828918 | Management of Narcolepsy. |
| Q37999096 | Models for narcolepsy with cataplexy drug discovery |
| Q41995022 | Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. |
| Q37807703 | Narcolepsy and cataplexy |
| Q33351116 | Narcolepsy and orexins: an example of progress in sleep research |
| Q36600966 | Narcolepsy and the hypocretin system--where motion meets emotion |
| Q30362783 | Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. |
| Q37762255 | Narcolepsy in Parkinson's disease |
| Q36733271 | Narcolepsy with cataplexy |
| Q35212990 | Narcolepsy: a review |
| Q36364195 | Narcolepsy: a review of evidence for autoimmune diathesis |
| Q34843237 | Narcolepsy: current treatment options and future approaches |
| Q27004322 | Narcolepsy: neural mechanisms of sleepiness and cataplexy |
| Q36675494 | Neuropeptides as possible targets in sleep disorders |
| Q37691690 | New developments in the management of narcolepsy |
| Q44871025 | Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models |
| Q46417496 | Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). |
| Q38287212 | Optogenetic control of hypocretin (orexin) neurons and arousal circuits |
| Q30485386 | Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice |
| Q38077489 | Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status |
| Q45233267 | Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. |
| Q39026714 | Orexin OX2 Receptor Antagonists as Sleep Aids |
| Q36980393 | Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. |
| Q36790716 | Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice |
| Q34696872 | Orexin neuronal circuitry: role in the regulation of sleep and wakefulness |
| Q34031925 | Orexin neurons receive glycinergic innervations |
| Q36390842 | Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity |
| Q36018973 | Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. |
| Q40228739 | Orexin receptor subtype activation and locomotor behaviour in the rat. |
| Q33717450 | Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action |
| Q40224903 | Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function |
| Q38950999 | Orexin/hypocretin activates mTOR complex 1 (mTORC1) via an Erk/Akt-independent and calcium-stimulated lysosome v-ATPase pathway. |
| Q37522864 | Orexin/hypocretin receptor signalling: a functional perspective |
| Q44094935 | Orexinergic activity modulates altered vital signs and pituitary hormone secretion in experimental sepsis. |
| Q41965823 | Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling |
| Q48507943 | Orexins, energy balance, temperature, sleep-wake cycle |
| Q35678386 | Orexins/hypocretins acting at Gi protein-coupled OX 2 receptors inhibit cyclic AMP synthesis in the primary neuronal cultures. |
| Q38690847 | Pharmacological management of narcolepsy with and without cataplexy |
| Q26822470 | Physiology of the orexinergic/hypocretinergic system: a revisit in 2012 |
| Q92690906 | Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation |
| Q34607196 | Promotion of sleep by targeting the orexin system in rats, dogs and humans |
| Q38794700 | RBD and Neurodegenerative Diseases |
| Q48293539 | Recent advances in the treatment of narcolepsy |
| Q36774914 | Role of orexin in modulating arousal, feeding, and motivation |
| Q27028141 | Role of orexin receptors in obesity: from cellular to behavioral evidence |
| Q89713817 | Role of spontaneous and sensory orexin network dynamics in rapid locomotion initiation |
| Q34989372 | Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy |
| Q36946754 | Selective Fos induction in hypothalamic orexin/hypocretin, but not melanin-concentrating hormone neurons, by a learned food-cue that stimulates feeding in sated rats |
| Q37132728 | Selective loss of GABA(B) receptors in orexin-producing neurons results in disrupted sleep/wakefulness architecture. |
| Q43130890 | Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice |
| Q36356595 | Stress and arousal: the corticotrophin-releasing factor/hypocretin circuitry. |
| Q34443676 | Suvorexant for the treatment of insomnia |
| Q34730569 | Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. |
| Q36375246 | The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors |
| Q34975026 | The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold |
| Q33915877 | The evolving story of orexin biology: the hits keep coming |
| Q36985867 | The hypocretin/orexin receptor: therapeutic prospective in sleep disorders |
| Q38231949 | The hypocretin/orexin system: an increasingly important role in neuropsychiatry. |
| Q34575514 | The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness |
| Q90463916 | The neurobiological basis of narcolepsy |
| Q24532097 | Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results |
| Q38828355 | Treatment Options for Narcolepsy |
| Q39311775 | Understanding sleep-wake mechanisms and drug discovery. |
| Q26827736 | Unmet needs of patients with narcolepsy: perspectives on emerging treatment options |
| Q34443394 | Wake-promoting pharmacotherapy for psychiatric disorders |
Search more.